CA-SOLIDIGM
6.8.2024 17:22:27 CEST | Business Wire | Press release
Today, Solidigm, a leading provider of innovative NAND flash memory solutions, announced the launch of the SolidigmTM D7-PS1010 and D7-PS1030 data center solid-state drives (SSDs). As the fastest PCIe 5.0 SSDs1 shipping in volume today, these drives are well suited for the IO intensity found in modern mainstream, mixed, and write-centric workloads.
“The Solidigm D7-PS1010 and D7-PS1030 SSDs were meticulously engineered to meet the increasingly demanding IO requirements across a range of workloads such as general-purpose servers, OLTP, server-based storage, decision support systems and AI/ML,” said Greg Matson, Senior Vice President of Strategic Planning and Marketing at Solidigm. “In a world where every watt counts, these drives are PCIe 5.0 done right, not only delivering industry-leading four-corner performance,2 but also up to 70% better energy efficiency compared to similar drives by other manufacturers.3”
Available in E3.S and U.2 form factors, the newest Solidigm SSDs come in a range of capacities and endurance options and are a strong extension to the company’s portfolio of best-in-industry storage for AI.
D7-PS1010
A standard endurance (SE) drive, the Solidigm D7-PS1010 is available in 1.92TB, 3.84TB, 7.68TB, and 15.36TB capacities. Over a 5-year period, the SE models provide 1.0 drive writes per day (DWPD) and boast substantial maximum lifetime program/erase cycles, with 28 petabytes written (PBW) for the 15.36TB variant. In server-based storage solutions, the D7-PS1010 can accelerate sequential write throughput up to 37 percent faster than drives with similar specifications.4 Offering a balance of performance and capacity, this drive is ideal for a wide range of mainstream applications.
D7-PS1030
A mid-endurance (ME) drive, the Solidigm D7-PS1030 is available in 1.6TB, 3.2TB, 6.4TB, and 12.8TB capacities and offers an impressive 70 PBW for the 12.8TB variant. When placed in an all-flash performance tier for AI workloads, the D7-PS1030 helps overcome hard disk drive (HDD) performance, endurance, and reliability limitations. With write performance more than double that of the previous generation Solidigm drive,5 the D7-PS1030 is particularly suited for operations requiring write-intensive usages such as caching and checkpointing.
The new drives are built to excel at every stage of the AI data pipeline and deliver up to 50 percent higher throughput in certain pipeline phases6 compared to similar drives in their class. These SSDs can be deployed as GPU direct attach drives in GPU servers or as part of a high-performance all-flash tier supporting lower-performing HDDs in network attach storage configurations.
“As AI workloads continue to surge, storage performance becomes critical,” said Ace Stryker, Director of Market Development at Solidigm. “The Solidigm D7-PS1010 and D7-PS1030 are a game-changer for AI-driven enterprises, capable of outperforming competitors at critical stages of the AI pipeline.”
With this launch, Solidigm continues its commitment to delivering industry-leading quality and reliability. By employing methodologies like testing to zero tolerance for data errors,7 built-in redundancies, enhanced power loss management, and engineering for performance consistency over the life of the drive,8 these SSDs far surpass required industry specifications and common practices. Combined with new OCP-compliant thermal management capabilities, and new security capabilities such as secure boot and data at rest protection and attestation, the D7-PS1010 and D7-PS1030 drives are designed to be deployed with utmost confidence in cloud and enterprise usages.
For more information on how Solidigm D7-PS1010 and Solidigm D7-PS1030 drives can help you power your workloads, visit our website.
About Solidigm
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of team members in 13 locations around the world. For more information, please visit solidigm.com and follow us on Twitter and on LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).
______________________
1 Comparing product specifications and measured real-life workload performance across widely shipping PCIe 5.0 data center SSDs at the industry’s highest volume capacity point of 3.84TB (using Solidigm 2023 and 2024 shipments as industry representative data).
2 Four-corner comparison data is based on publicly available information from Samsung, Kioxia, and Micron.
3 Comparing 7.68TB, Samsung PM1743 and Solidigm D7-PS1010. Power is measured using Quarch Technology. Solidigm D7-PS1010 (128KB SW QD128 IOPS/Watt 3,874), Samsung PM1743 (128KB SW QD128 IOPS/Watt 2,272).
4 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. Comparing SolidigmTM D7-PS1010 3.84TB (128KB Seq Write QD128 8.2 MB/s) vs Samsung PM1743 3.84TB (128KB Seq Write QD128 6.0 MB/s).
5 As compared to previous generation Solidigm™ D7-P5520 and D7-P5620.
6 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. SolidigmTM D7-PS1010 7.68TB (32KB SW QD32 9.03GB/s 113us) vs Samsung PM1743 7.68TB (32K SW QD32 6.03GB/s 170us).
7 Solidigm drives are tested to 1E-18 under full range of conditions and cycle counts throughout the life of the drive which is 100X higher than 1E-16 specified in JEDEC – Solid State Drive Requirements and Endurance Test Method (JESD218). https://www.jedec.org/standards-documents/focus/flash/solid-state-drives.
8 Refer to SolidigmTM D7-PS1010 product specifications for IOPS consistency. Solidigm expects up to 5% variation in throughput between drive-to-drive runs. IOPS variability measured after adjusting SSD cycle limit to simulate end of life behavior. Results are estimated or simulated. Actual results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806563458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom